GLFD Guilford Pharmaceuticals (MM)

Guilford Pharmaceuticals Appoints David C. U'Prichard to Its Board of Directors BALTIMORE, Dec. 1 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. announced today that it has appointed David U'Prichard, Ph.D., to the Company's Board of Directors and to the Board's Science Committee, effective November 18, 2003. "We are extremely honored to welcome Dr. U'Prichard as a member of Guilford's Board of Directors," commented Craig R. Smith, M.D., Chairman, President and Chief Executive Officer. "As an accomplished industry professional and former member of the board of directors of the Biotechnology Industry Organization, Dr. U'Prichard's unique combination of experience and expertise in the life sciences industry will provide invaluable assistance to our Company as we concentrate on achieving our strategic objective of accelerating Guilford's transition to profitability." Dr. U'Prichard currently serves as President of Druid Consulting LLC, a specialized pharmaceutical and biotechnology consulting firm, which provides customized services to life sciences clients in the United States and Europe. Dr. U'Prichard is also a Venture Partner and member of the health care team of Apax Partners Ltd., a global private equity provider. Prior thereto, he served as Chief Executive Officer of 3-Dimensional Pharmaceuticals (3DP) from 1999 to 2003. During his tenure at 3DP, Dr. U'Prichard was responsible for leading the private biotechnology company's successful initial public offering, and completing major corporate alliances with Bristol-Myers Squibb Company and Johnson & Johnson Pharmaceutical Research and Development, L.L.C. In January 2003, he successfully negotiated the acquisition of 3DP by Johnson & Johnson Pharmaceutical Research and Development, L.L.C. In addition to his service at 3DP, Dr. U'Prichard has held a variety of positions within the pharmaceutical and biotechnology industries. Prior to serving as Chief Executive Officer at 3DP, Dr. U'Prichard acted as President and Chairman of Research and Development for SmithKline Beecham Pharmaceuticals; Executive Vice President and International Research Director, and a Member of the Board of Zeneca Pharmaceuticals; General Manager Research Department, ICI Pharmaceuticals and Vice President Biomedical Research, ICI Pharmaceuticals, and Senior Vice President and Scientific Director for Nova Pharmaceutical Corporation. He currently serves as a member of the board of directors of the Life Sciences Research Foundation in Baltimore, Maryland, and is a member of the board of directors of Lynx Therapeutics, ExSAR Corporation and Predict, Inc. Dr. U'Prichard is also Chairman of the board of directors for the Pennsylvania Biotechnology Association. From 1992 to 1997 Dr. U'Prichard was a member of the board of the Biotechnology Industry Organization (BIO), an international association of more than 1,000 biotechnology companies, academic institutions, biotechnology research centers and related organizations representing 33 nations. Dr. U'Prichard holds a B.Sc. in pharmacology from the University of Glasgow and a M.Sc. and Ph.D. in pharmacology from the University of Kansas. He was also a tenured Associate Professor in the Departments of Pharmacology, Neurobiology and Physiology in the College of Arts and Sciences at Northwestern University, and has held adjunct academic appointments at the Johns Hopkins University, the University of Pennsylvania and the University of Maryland. He is an Honorary Professor of Glasgow University, Scotland. About Guilford Guilford Pharmaceuticals Inc. is a fully integrated pharmaceutical company engaged in the research, development and commercialization of products that target the hospital market. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer and AGGRASTAT(R) Injection. Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and post-prostatectomy erectile dysfunction. This press release contains forward-looking statements that involve risks and uncertainties, including those described in the section entitled "Risk Factors" contained in the Company's quarterly report on Form 10-Q filed with the SEC on November 12, 2003, that could cause the Company's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Contact: Guilford Pharmaceuticals Inc. Stacey Jurchison 410.631.5022 Internet addresses: http://www.guilfordpharm.com/ DATASOURCE: Guilford Pharmaceuticals Inc. CONTACT: Stacey Jurchison, Guilford Pharmaceuticals, +1-410-631-5022, Web site: http://www.guilfordpharm.com/ Company News On-Call: http://www.prnewswire.com/comp/112882.html

Copyright